143 related articles for article (PubMed ID: 2842508)
41. Topoisomerization of plasmid DNA in Escherichia coli infected with bacteriophage T4.
Albright LM; Geiduschek EP
J Mol Biol; 1986 Aug; 190(3):329-41. PubMed ID: 3023639
[TBL] [Abstract][Full Text] [Related]
42. Mutagenic specificity of nitrosomethylurea in bacteriophage T4.
Ripley LS
Mutat Res; 1981 Aug; 83(1):1-14. PubMed ID: 7024791
[TBL] [Abstract][Full Text] [Related]
43. Nucleotide sequence of the lysozyme gene of bacteriophage T4. Analysis of mutations involving repeated sequences.
Owen JE; Schultz DW; Taylor A; Smith GR
J Mol Biol; 1983 Apr; 165(2):229-48. PubMed ID: 6302287
[TBL] [Abstract][Full Text] [Related]
44. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
[TBL] [Abstract][Full Text] [Related]
45. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
46. Differential selection of acridine resistance mutations in human DNA topoisomerase IIbeta is dependent on the acridine structure.
Leontiou C; Watters GP; Gilroy KL; Heslop P; Cowell IG; Craig K; Lightowlers RN; Lakey JH; Austin CA
Mol Pharmacol; 2007 Apr; 71(4):1006-14. PubMed ID: 17209120
[TBL] [Abstract][Full Text] [Related]
47. Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent.
Ebert SN; Shtrom SS; Muller MT
J Virol; 1990 Sep; 64(9):4059-66. PubMed ID: 2166804
[TBL] [Abstract][Full Text] [Related]
48. Mutagenicity of acridines in a reversion assay based on tetracycline resistance in plasmid pBR322 in Escherichia coli.
Hoffman GR; Deschênes SM; Manyin T; Fuchs RP
Mutat Res; 1996 Mar; 351(1):33-43. PubMed ID: 8602172
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms of spontaneous and induced frameshift mutation in bacteriophage T4.
Streisinger G; Owen J
Genetics; 1985 Apr; 109(4):633-59. PubMed ID: 3988038
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds.
Janočková J; Plšíková J; Kašpárková J; Brabec V; Jendželovský R; Mikeš J; Kovaľ J; Hamuľaková S; Fedoročko P; Kuča K; Kožurková M
Eur J Pharm Sci; 2015 Aug; 76():192-202. PubMed ID: 25960253
[TBL] [Abstract][Full Text] [Related]
51. Purification and characterization of the SegA protein of bacteriophage T4, an endonuclease related to proteins encoded by group I introns.
Sharma M; Hinton DM
J Bacteriol; 1994 Nov; 176(21):6439-48. PubMed ID: 7961394
[TBL] [Abstract][Full Text] [Related]
52. Acridine derivatives as inhibitors/poisons of topoisomerase II.
Kozurkova M
J Appl Toxicol; 2022 Apr; 42(4):544-552. PubMed ID: 34514603
[TBL] [Abstract][Full Text] [Related]
53. Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.
Kreuzer KN
Biochim Biophys Acta; 1998 Oct; 1400(1-3):339-47. PubMed ID: 9748648
[TBL] [Abstract][Full Text] [Related]
54. Frameshift mutation in the lysozyme gene of bacteriophage T4: demonstration of the insertion offour bases and the preferential occurrence of base addition in acridine mutagenesis.
Imada M; Inouye M; Eda M; Tsugita A
J Mol Biol; 1970 Dec; 54(2):199-217. PubMed ID: 4924202
[No Abstract] [Full Text] [Related]
55. Frameshift mutations induced by three classes of acridines in the lacZ reversion assay in Escherichia coli: potency of responses and relationship to slipped mispairing models.
Hoffmann GR; Calciano MA; Lawless BM; Mahoney KM
Environ Mol Mutagen; 2003; 42(2):111-21. PubMed ID: 12929124
[TBL] [Abstract][Full Text] [Related]
56. The genetic toxicology of acridines.
Ferguson LR; Denny WA
Mutat Res; 1991 Sep; 258(2):123-60. PubMed ID: 1881402
[TBL] [Abstract][Full Text] [Related]
57. The 52-protein subunit of T4 DNA topoisomerase is homologous to the gyrA-protein of gyrase.
Huang WM
Nucleic Acids Res; 1986 Sep; 14(18):7379-90. PubMed ID: 3020513
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of T4 bacteriophage yield by 9-anilinoacridines; comparison with in vivo antitumour activity.
Robertson IG; Denny WA; Baguley BC
Eur J Cancer (1965); 1980 Sep; 16(9):1133-9. PubMed ID: 7227441
[No Abstract] [Full Text] [Related]
59. Demonstration of the production of frameshift and base-substitution mutations by quasipalindromic DNA sequences.
de Boer JG; Ripley LS
Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5528-31. PubMed ID: 6089210
[TBL] [Abstract][Full Text] [Related]
60. Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.
Freudenreich CH; Kreuzer KN
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11007-11. PubMed ID: 7971998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
